Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and ...

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says ...

Explore essential mental health support strategies for older adults with cancer, addressing grief, community resources, and ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Nurses should be familiar with PET scan protocol and what to ask patients with lung and bone cancers before administering ...

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, ...

C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.